A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study is for patients with biliary tract cancer that has spread and who are not
candidates for surgical resection.
The purpose of this research is to determine if bevacizumab can be safely administered with
Modified FOLFOX 6 and find out what effects, good and/or bad, this type of treatment has on
biliary cancer.
In this study, a combination of chemotherapy, Modified FOLFOX6 and a biologic agent,
bevacizumab will be tested.
Subjects on this study will receive chemotherapy and bevacizumab every 2 weeks until their
disease gets worse or they are unable to tolerate treatment.